1. Chua YJ, Steer C, Yip D. Recent advances in management of small-cell lung cancer. Cancer Treat Rev 2004;30:521-543. PMID:
15325033.
2. Usuda K, Saito Y, Sagawa M, Sato M, Kanma K, Takahashi S, et al. Tumor doubling time and prognostic assessment of patients with primary lung cancer. Cancer 1994;74:2239-2244. PMID:
7922975.
3. Tanaka K, Shimada H, Miura M, Fujii Y, Yamaguchi S, Endo I, et al. Metastatic tumor doubling time: most important prehepatectomy predictor of survival and nonrecurrence of hepatic colorectal cancer metastasis. World J Surg 2004;28:263-270. PMID:
14961200.
5. Ost D, Fein AM, Feinsilver SH. Clinical practice. The solitary pulmonary nodule. N Engl J Med 2003;348:2535-2542. PMID:
12815140.
7. Paesmans M, Sculier JP, Lecomte J, Thiriaux J, Libert P, Sergysels R, et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer 2000;89:523-533. PMID:
10931451.
8. Ando S, Suzuki M, Yamamoto N, Iida T, Kimura H. The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer. Anticancer Res 2004;24:1941-1946. PMID:
15274381.
9. Ou SH, Ziogas A, Zell JA. Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity. J Thorac Oncol 2009;4:37-43. PMID:
19096304.
10. Singh S, Parulekar W, Murray N, Feld R, Evans WK, Tu D, et al. Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J Clin Oncol 2005;23:850-856. PMID:
15681530.
11. Micke P, Faldum A, Metz T, Beeh KM, Bittinger F, Hengstler JG, et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer--what limits limited disease? Lung Cancer 2002;37:271-276. PMID:
12234695.
12. National Comprehensive Cancer Network. The NCCN clinical practice guidelines in oncology: small cell lung cancer (version V.II.2014) [Internet]. Fort Washington: National Comprehensive Cancer Network; 2013. cited 2013 Oct 3. Available from:
http://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf.
13. Wang CS, Sun CF. C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. Chang Gung Med J 2009;32:471-482. PMID:
19840504.
14. McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 2003;90:215-219. PMID:
12555298.
15. Nozoe T, Saeki H, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg 2001;182:197-201. PMID:
11574097.
16. Nagaoka S, Yoshida T, Akiyoshi J, Akiba J, Torimura T, Adachi H, et al. Serum C-reactive protein levels predict survival in hepatocellular carcinoma. Liver Int 2007;27:1091-1097. PMID:
17845537.
17. Hara M, Matsuzaki Y, Shimuzu T, Tomita M, Ayabe T, Enomoto Y, et al. Preoperative serum C-reactive protein level in non-small cell lung cancer. Anticancer Res 2007;27:3001-3004. PMID:
17695486.
20. Arpin D, Trillet-Lenoir V, Lasset C, Souquet PJ, Riou R, Yoanidis I, et al. [Value of C-reactive protein determination in small cell lung cancer]. Bull Cancer 1993;80:1063-1068. PMID:
8081044.
21. Hong S, Kang YA, Cho BC, Kim DJ. Elevated serum C-reactive protein as a prognostic marker in small cell lung cancer. Yonsei Med J 2012;53:111-117. PMID:
22187240.
22. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3 1973;4:31-42. PMID:
4580860.
23. Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, Chansky K, et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2007;2:1067-1077. PMID:
18090577.
25. Bergmann L, Hirschfeld S, Morris C, Palmeri S, Stone A. Progression-free survival as an end-point in clinical trials of biotherapeutic agents. Eur J Cancer Suppl 2007;5:23-28.
26. Dancey JE, Dodd LE, Ford R, Kaplan R, Mooney M, Rubinstein L, et al. Recommendations for the assessment of progression in randomised cancer treatment trials. Eur J Cancer 2009;45:281-289. PMID:
19097775.
27. Buyse M, Burzykowski T, Carroll K, Michiels S, Sargent DJ, Miller LL, et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 2007;25:5218-5224. PMID:
18024867.
29. Amir E, Seruga B, Kwong R, Tannock IF, Ocana A. Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer? Eur J Cancer 2012;48:385-388. PMID:
22115991.
30. Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005;366:1385-1396. PMID:
16226617.
31. Johnson BE, Makuch RW, Simmons AD, Gazdar AF, Burch D, Cashell AW. myc family DNA amplification in small cell lung cancer patients' tumors and corresponding cell lines. Cancer Res 1988;48:5163-5166. PMID:
2842046.
32. Brennan J, O'Connor T, Makuch RW, Simmons AM, Russell E, Linnoila RI, et al. myc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens. Cancer Res 1991;51:1708-1712. PMID:
1847842.
33. Friberg S, Mattson S. On the growth rates of human malignant tumors: implications for medical decision making. J Surg Oncol 1997;65:284-297. PMID:
9274795.